Regeneron Pharmaceuticals (REGN)Rep. Jonathan Jackson (IL01) disclosed a sale $15K–$50K
Rep. Jonathan Jackson (IL01) disclosed a sale of Regeneron Pharmaceuticals in the $15K–$50K range.
- $15,001–$50,000
- Reported range · official band, not an exact amount
- 29 days
- Disclosure lag
- Traded
- Nov 13, 2024
- Disclosed
- Dec 12, 2024
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Sep 27, 2024FDAFDA drug approval: Dupixent
- Oct 1, 2024Insider · 2 peopleInsiders: 18 sales (~$1.2M)
- Oct 15, 2024CongressDisclosed sale of REGN — reported range $1,001 - $15,000
- Oct 23, 2024CongressDisclosed partial sale of REGN — reported range $1,001 - $15,000
- Nov 1, 2024InsiderOfficer sold ~$845K of REGN shares in the open market
- Nov 1, 2024CongressDisclosed partial sale of REGN — reported range $1,001 - $15,000
- Nov 13, 2024 · this disclosureCongressDisclosed sale of REGN — reported range $15,001 - $50,000
What came next
- Nov 19, 2024CongressDisclosed partial sale of REGN — reported range $1,001 - $15,000
- Nov 29, 2024CongressDisclosed partial sale of REGN — reported range $1,001 - $15,000
- Jan 7, 2025Court · District Court, S.D. New YorkSecurities lawsuit filed: In re Regeneron Pharmaceuticals, Inc. Securities Litigation
- Jan 15, 2025CongressDisclosed purchase of REGN — reported range $1,001 - $15,000
- Jan 24, 2025CongressDisclosed sale of REGN — reported range $1,001 - $15,000
- Feb 12, 2025CongressDisclosed partial sale of REGN — reported range $1,001 - $15,000
How to read House Clerk periodic transaction report
The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.
Full guide: What is the STOCK Act?
What else is on file for Regeneron Pharmaceuticals
For Regeneron Pharmaceuticals, OQRO holds 8 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 31 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its REGN page.
Other recent filings by Rep. Jonathan Jackson (IL01)
- House Clerk periodic transaction report at Viasat, Inc. (VSAT)Sep 3, 2026
- House Clerk periodic transaction report at Hilton Worldwide (HLT)Jul 15, 2026
- House Clerk periodic transaction report at McKesson Corporation (MCK)Jul 15, 2026
- House Clerk periodic transaction report at Sphere Entertainment (SPHR)Jul 15, 2026
- House Clerk periodic transaction report at Microsoft (MSFT)Jun 16, 2026
The full history of Rep. Jonathan Jackson (IL01) is on the profile page.
How this filing works
Other disclosures at Regeneron Pharmaceuticals
- SEC Form 144Sep 3, 2026
- SEC Form 4Sep 3, 2026
- SEC Form 4Sep 3, 2026
- SEC Form 4Sep 3, 2026
- SEC Form 144Sep 2, 2026
- SEC Form 144Sep 2, 2026
Everything OQRO holds on this company is on its REGN page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data